Cellid Co. Ltd (299660) - Total Liabilities
Based on the latest financial reports, Cellid Co. Ltd (299660) has total liabilities worth ₩36.66 Billion KRW (≈ $24.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cellid Co. Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how Cellid Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Cellid Co. Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cellid Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Cellid Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shengfeng Development Limited Class A Ordinary Shares
NASDAQ:SFWL
|
USA | $166.27 Million |
|
VisionWave Holdings, Inc. Common Stock
NASDAQ:VWAV
|
USA | $37.06 Million |
|
Shandong Chenming Paper Holdings Limited
F:SCD1
|
Germany | €48.86 Billion |
|
Plata Latina Minerals Corp
V:PLA
|
Canada | CA$60.71K |
|
DNA Biomed Solns
TA:DNA
|
Israel | ILA1.77 Million |
|
Dierig Holding AG
XETRA:DIE
|
Germany | €76.08 Million |
|
Shanghai Material Trading Co Ltd B
SHG:900927
|
China | $463.81 Million |
|
Redwood Group Ltd
TWO:8426
|
Taiwan | NT$1.27 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Cellid Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 299660 total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellid Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellid Co. Ltd (2015–2025)
The table below shows the annual total liabilities of Cellid Co. Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩36.66 Billion ≈ $24.85 Million |
+47.34% |
| 2024-12-31 | ₩24.88 Billion ≈ $16.86 Million |
+6.22% |
| 2023-12-31 | ₩23.43 Billion ≈ $15.88 Million |
+0.04% |
| 2022-12-31 | ₩23.42 Billion ≈ $15.87 Million |
+20.12% |
| 2021-12-31 | ₩19.50 Billion ≈ $13.21 Million |
+826.53% |
| 2020-12-31 | ₩2.10 Billion ≈ $1.43 Million |
+77.41% |
| 2019-12-31 | ₩1.19 Billion ≈ $803.76K |
+64.58% |
| 2018-12-31 | ₩720.63 Million ≈ $488.36K |
-93.13% |
| 2017-12-31 | ₩10.49 Billion ≈ $7.11 Million |
+161.36% |
| 2016-12-31 | ₩4.01 Billion ≈ $2.72 Million |
+114.39% |
| 2015-12-31 | ₩1.87 Billion ≈ $1.27 Million |
-- |
About Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) an… Read more